GlobeNewswire

Valmet to supply new bleach plant and upgrade of batch cooking and fiberline to ITC's Bhadrachalam pulp mill in India

Share

Valmet Oyj’s press release on August 27, 2020 at 1:00 p.m. EET

Valmet will deliver a new bleach plant and upgrade of the batch cooking and fiberline to ITC's Bhadrachalam pulp mill in India.

The order is included in Valmet's orders received of the third quarter 2020. The order value will not be disclosed. An order of this scope is typically around EUR 20-30 million. The start-up is scheduled for 2022.

The Bhadrachalam pulp mill has an increased demand of pulp due to continuous expansion in board production. The company has recently invested in Valmet’s board machine, a new high power recovery boiler and ash leaching plant.

“Valmet has been a trusted partner for our paperboard and chemical pulp lines and has constantly put efforts in research and development of the operation issues and input condition changes. For this reason, ITC's management chose Valmet as the supplier of the new bleach plant,” says Sanjay Singh, Divisional Chief Executive, ITC Limited, Paperboards and Specialty Papers Division.

"Valmet and ITC have put a lot of effort into a thorough pre-engineering aiming at increasing the production, reducing operating costs and improving the fiberline’s availability. I am happy to say that the outcome is a state-of-the-art process solution combining existing equipment with the latest technology, which will allow ITC to increase its pulp production with improved pulp quality at reduced cost per ton of pulp. This project is the result of good cooperation between ITC and Valmet, and we are committed to continuing to support ITC with the latest technology and strong local presence in India," says Varun Jain, Director, India Region, Valmet.

Information about Valmet’s delivery

Valmet’s delivery includes new bleach plant, batch cooking extension and fiberline upgrade. The supply scope consists of main equipment, basic engineering, training, site services and corresponding spare parts. In addition to this, the delivery also includes Valmet Industrial Internet VII for Pulp Quality solutions for the new bleach plant in order to secure reliable and efficient operation.

Information about the customer ITC Limited

ITC Paperboards and Specialty Papers Division is among the leaders in the paper and paperboard business with solutions to meet a diverse cross-section of packaging and communication needs. With emphasis on harnessing technology, the company has emerged as the largest manufacturer of packaging and graphic boards in South Asia. ITC's Paper Board and Specialty Paper's Division has eleven machines at three locations with production capacity of 800,000 tons per annum. End-market products are surface sized printing and writing papers, non-surface sized printing and writing papers, paperboards and coated boards.

VALMET
Corporate Communications

For further information, please contact:

Varun Jain, Director, India Region, Valmet, tel. +91 96548 13696
NK Jain, Head Capital Sales, India Region, Valmet, tel. +91 987325 1858
Eva Engelfeldt, Senior Sales Manager, Pulp and Energy business line, Valmet, tel. +46 706 80 52 19

Valmet is the leading global developer and supplier of process technologies, automation and services for the pulp, paper and energy industries. We aim to become the global champion in serving our customers.

Valmet's strong technology offering includes pulp mills, tissue, board and paper production lines, as well as power plants for bioenergy production. Our advanced services and automation solutions improve the reliability and performance of our customers' processes and enhance the effective utilization of raw materials and energy.

Valmet's net sales in 2019 were approximately EUR 3.5 billion. Our more than 13,000 professionals around the world work close to our customers and are committed to moving our customers' performance forward - every day. Valmet's head office is in Espoo, Finland and its shares are listed on the Nasdaq Helsinki.

Read more www.valmet.com, www.twitter.com/valmetglobal

Processing of personal data

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease1.12.2020 22:01:00 CETPress release

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737. The drug candidate or placebo will be administered for 52 weeks in up to 60 ADPKD patients with rapidly progressing disease. Patients will be randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary measures include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial is planned in 7 countries in Europe. GLPG2737 is a CFTR1 inhibitor which was shown to be well tolerated by patients in previous clinical trials. It is hypothesi

REC Silicon – Cancellation of subsequent offering1.12.2020 20:13:46 CETPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Lysaker, 1 December 2020 Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement") and a potential subsequent offering (the "Subsequent Offering") of up to 18,518,518 new shares directed towards shareholders of the Company as of 14 October 2020 who were not allocated shares in the Private Placement. The Company has decided not to initiate the Subsequent Offering. The background for the cancellation is that the Company's shares have over time traded on the Oslo Stock Exchange, with significant trading volume, at prices below the subscription pric

Bombardier and Alstom Confirm Receipt of All Necessary Regulatory Approvals to Complete Bombardier Transportation Sale to Alstom1.12.2020 18:24:09 CETPress release

MONTRÉAL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) and Alstom announced today that all necessary regulatory approvals required to complete the sale of Bombardier Transportation to Alstom have been received. Bombardier and Alstom now expect the transaction to close on January 29, 2021. About Bombardier With over 52,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are availab

FDA approves Xolair® (omalizumab) for adults with nasal polyps1.12.2020 18:07:00 CETPress release

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammationXolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key d

Tecan raises forecast for the full year of 2020 based on continued extraordinary demand for COVID-19 related products1.12.2020 18:02:00 CETPress release

Sales growth now expected to be in the low to mid-teens percentage range in local currenciesReported EBITDA margin now forecasted above 20.5% of sales Männedorf, Switzerland, 1 December, 2020 – Based on the strong business performance year to date, as well as on the high order backlog and the continued elevated demand for COVID-19 related products, the Tecan Group (SIX Swiss Exchange: TECN) once again raised its outlook for full-year sales and reported EBITDA margin. These updated projections continue to be based on the assumptions that also for the remainder of the year supply chains and freight logistics remain undisrupted and all production sites stay fully operational. Based on continued strong demand for a number of product lines to help in the global fight against the coronavirus pandemic, Tecan now forecasts sales growth for full-year 2020 to be in the low to mid-teens percentage range in local currencies (latest guidance from August 12, 2020: “high single-digit percentage range

Touax: Successful asset refinancing - Containers Business1.12.2020 17:45:00 CETPress release

PRESS RELEASE Paris, December 1, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Successful asset refinancing - Containers Business Touax announces today that it has successfully refinanced asset-backed facilities of its Container division for a total of US$ 75 million, versus US$ 60 million previously, combining a Term Loan of US$ 37 million and a Revolving Credit Facility (RCF) of US$ 38 million with a two-year maturity. The documentation provides for an accordion option, allowing the line to be scaled up to US$ 85 million, to support growth. This operation allows the refinancing of the existing portfolio of assets as well as the financing of future investments. Touax Container Asset Finance Ltd will thus continue to invest for its development, particularly in the purchase of equipment for leasing purpose. Financing is granted by ABN AMRO Bank N.V., ING Belgium SA / NV and NIBC Bank N.V. Touax was advised by Stephenson Harwood (Legal Counsel). “We ar